» Articles » PMID: 34321470

SUMOylation of SAMHD1 at Lysine 595 is Required for HIV-1 Restriction in Non-cycling Cells

Abstract

SAMHD1 is a cellular triphosphohydrolase (dNTPase) proposed to inhibit HIV-1 reverse transcription in non-cycling immune cells by limiting the supply of the dNTP substrates. Yet, phosphorylation of T592 downregulates SAMHD1 antiviral activity, but not its dNTPase function, implying that additional mechanisms contribute to viral restriction. Here, we show that SAMHD1 is SUMOylated on residue K595, a modification that relies on the presence of a proximal SUMO-interacting motif (SIM). Loss of K595 SUMOylation suppresses the restriction activity of SAMHD1, even in the context of the constitutively active phospho-ablative T592A mutant but has no impact on dNTP depletion. Conversely, the artificial fusion of SUMO2 to a non-SUMOylatable inactive SAMHD1 variant restores its antiviral function, a phenotype that is reversed by the phosphomimetic TE mutation. Collectively, our observations clearly establish that lack of T592 phosphorylation cannot fully account for the restriction activity of SAMHD1. We find that SUMOylation of K595 is required to stimulate a dNTPase-independent antiviral activity in non-cycling immune cells, an effect that is antagonized by cyclin/CDK-dependent phosphorylation of T592 in cycling cells.

Citing Articles

Regulation of viral replication by host restriction factors.

Lin Y, Zhu Y, Jing L, Lei X, Xie Z Front Immunol. 2025; 16:1484119.

PMID: 39917304 PMC: 11798991. DOI: 10.3389/fimmu.2025.1484119.


E2 Ubiquitin-Conjugating Enzymes Regulates Dengue Virus-2 Replication in .

Wang J, Zheng X, Wang X, Zhong D, Zhou G Microorganisms. 2025; 12(12.

PMID: 39770712 PMC: 11676440. DOI: 10.3390/microorganisms12122508.


Acetylation of SAMHD1 at lysine 580 is crucial for blocking HIV-1 infection.

Bulnes-Ramos A, Schott K, Rabinowitz J, Luchsinger C, Bertelli C, Miyagi E mBio. 2024; 15(9):e0195824.

PMID: 39162568 PMC: 11389391. DOI: 10.1128/mbio.01958-24.


Host cell restriction factors of equine infectious anemia virus.

Wang X, Zhang X, Ma W, Li J, Wang X Virol Sin. 2023; 38(4):485-496.

PMID: 37419416 PMC: 10436108. DOI: 10.1016/j.virs.2023.07.001.


Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies.

Wang T, Liu P, Yang J Genes Dis. 2023; 10(3):891-900.

PMID: 37396510 PMC: 10308132. DOI: 10.1016/j.gendis.2022.06.001.


References
1.
Baldauf H, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M . SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012; 18(11):1682-7. PMC: 3828732. DOI: 10.1038/nm.2964. View

2.
Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y . SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology. 2012; 9:87. PMC: 3494655. DOI: 10.1186/1742-4690-9-87. View

3.
Hrecka K, Hao C, Gierszewska M, Swanson S, Kesik-Brodacka M, Srivastava S . Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011; 474(7353):658-61. PMC: 3179858. DOI: 10.1038/nature10195. View

4.
Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E . SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011; 474(7353):654-7. PMC: 3595993. DOI: 10.1038/nature10117. View

5.
Goldstone D, Ennis-Adeniran V, Hedden J, Groom H, Rice G, Christodoulou E . HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011; 480(7377):379-82. DOI: 10.1038/nature10623. View